Pharma BD Deal Intelligence
KKR's industrials team led the deal, framing Capsugel as an engineering/manufacturing platform with emerging-markets and gelatin-free growth options rather…
Pfizer's sale of its Capsugel unit to KKR signals that more non-core divestitures are likely as the pharma giant continues to streamline post-Wyeth integration.
Bernstein's Tim Anderson said Pfizer divestments looked serious and could extend beyond non-pharma units to Established Products — extremely bold but…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Pfizer announced April 5, 2011 the sale of Capsugel to KKR for ~$2.38B in cash; closed August 1, 2011. Capsugel is a leading pharma capsule and drug-delivery platform with ~$750M annual revenue.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Capsugel (Pfizer divestiture to KKR) (this deal) | 2011 | $2.4B | 71 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2011 deals · Pfizer Inc. deals · Other deals